Page 126 - TD-4-1

Tumor Discovery Pyrotinib and capecitabine in HER2-negative recurrence

Investigation: Yuling Zhang, Bingfeng Chen significance. Mod Pathol. 2012;25(7):938-948.
Methodology: Chunfa Chen doi: 10.1038/modpathol.2012.36
Writing–original draft: Yuling Zhang
Writing–review & editing: Chunfa Chen, Jundong Wu 7. Hou Y, Nitta H, Wei L, et al. HER2 intratumoral
heterogeneity is independently associated with incomplete
Ethics approval and consent to participate response to anti-HER2 neoadjuvant chemotherapy in
HER2-positive breast carcinoma. Breast Cancer Res Treat.
The study was approved by the Ethics Committee of the 2017;166(2):447-457.
Cancer Hospital of Shantou University Medical College
(approval no.: 2022139). doi: 10.1007/s10549-017-4453-8
8. Lee HJ, Seo AN, Kim EJ, et al. HER2 heterogeneity affects
Consent for publication trastuzumab responses and survival in patients with

Written informed consent was obtained from the patient HER2-positive metastatic breast cancer. Am J Clin Pathol.
2014;142(6):755-766.
for publication of the details of her medical case and any
accompanying images. A copy of the written consent is doi: 10.1309/AJCPIRL4GUVGK3YX
available for review by the Editor-in-Chief of this journal 9. Guarneri V, Dieci MV, Barbieri E, et al. Loss of HER2
upon request. positivity and prognosis after neoadjuvant therapy
in HER2-positive breast cancer patients. Ann Oncol.
Availability of data 2013;24(12):2990-2994.

Not applicable. doi: 10.1093/annonc/mdt364
References 10. Mittendorf EA, Wu Y, Scaltriti M, et al. Loss of HER2
amplification following trastuzumab-based neoadjuvant
1. Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast systemic therapy and survival outcomes. Clin Cancer Res.
cancer: changes in guidelines and complicating factors for 2009;15(23):7381-7388.
interpretation. J Pathol Transl Med. 2020;54(1):34-44.
doi: 10.1158/1078-0432.CCR-09-1735
doi: 10.4132/jptm.2019.11.03
11. Larionov AA. Current therapies for human epidermal
2. Niikura N, Tomotaki A, Miyata H, et al. Changes in growth factor receptor 2-positive metastatic breast cancer
tumor expression of HER2 and hormone receptors patients. Front Oncol. 2018;8:89.
status after neoadjuvant chemotherapy in 21,755 patients
from the Japanese breast cancer registry. Ann Oncol. doi: 10.3389/fonc.2018.00089
2016;27(3):480-487. 12. Suzuki T, Matsushima C, Nishimura S, Higashiyama T,
doi: 10.1093/annonc/mdv611 Sasabe M, Machida Y. Identification of phosphoinositide-
binding protein PATELLIN2 as a substrate of Arabidopsis
3. Katayama A, Miligy IM, Shiino S, et al. Predictors MPK4 MAP kinase during septum formation in cytokinesis.
of pathological complete response to neoadjuvant
treatment and changes to post-neoadjuvant HER2 status Plant Cell Physiol. 2016;57(8):1744-1755.
in HER2-positive invasive breast cancer. Mod Pathol. doi: 10.1093/pcp/pcw098
2021;34(7):1271-1281.
13. Singh DD, Lee HJ, Yadav DK. Clinical updates on tyrosine
doi: 10.1038/s41379-021-00738-5 kinase inhibitors in HER2-positive breast cancer. Front
4. Schrijver W, Suijkerbuijk KPM, van Gils CH, van der Wall E, Pharmacol. 2022;13:1089066.
Moelans CB, van Diest PJ. Receptor conversion in distant doi: 10.3389/fphar.2022.1089066
breast cancer metastases: A systematic review and meta-
analysis. J Natl Cancer Inst. 2018;110(6):568-580. 14. Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus
lapatinib plus capecitabine for the treatment of HER2-
doi: 10.1093/jnci/djx273 positive metastatic breast cancer (PHOEBE): A multicentre,
5. Merola R, Mottolese M, Orlandi G, et al. Analysis of open-label, randomised, controlled, phase 3 trial. Lancet
aneusomy level and HER-2 gene copy number and their Oncol. 2021;22(3):351-360.
effect on amplification rate in breast cancer specimens doi: 10.1016/S1470-2045(20)30702-6.
read as 2+ in immunohistochemical analysis. Eur J Cancer.
2006;42(10):1501-1506. 15. Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine
for patients with human epidermal growth factor receptor
doi: 10.1016/j.ejca.2006.03.011 2-positive breast cancer and brain metastases (PERMEATE):
6. Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 A multicentre, single-arm, two-cohort, phase 2 trial. Lancet
gene amplification in breast cancer: Its clinicopathological Oncol. 2022;23(3):353-361.

Volume 4 Issue 1 (2025) 118 doi: 10.36922/td.4093